A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials
Who is this study for? Patients with Multiple Sclerosis
What treatments are being studied? Ocrelizumab
Status: Completed
Location: See all (155) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Signed Informed Consent Form
• Able to comply with the study protocol, in the investigator's judgment
• Completed the treatment period of Roche sponsored ocrelizumab P-trials
Locations
Other Locations
Argentina
Hospital Churruca Visca
Buenos Aires
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Ciudad Autonoma Buenos Aires
Fundacion Rosarina de Neurorehabilitacion
Rosario
Belgium
AZ Sint Jan
Bruges
UZ Antwerpen
Edegem
CHU Tivoli
La Louvière
CHU de Liège (Sart Tilman)
Liège
Revalidatie en MS Centrum
Overpelt
Brazil
Instituto de Neurologia de Curitiba
Curitiba
Hospital Sao Lucas - PUCRS
Porto Alegre
Hospital das Clinicas - FMUSP
São Paulo
Bulgaria
Multiprofile Hosp. for Active Treatment
Sofia
Shat Np Sveti Naum
Sofia
Canada
Clinique NeuroOutaouais
Gatineau
Recherche Sepmus Inc.
Greenfield Park
London Health Sciences Centre Uni Campus
London
Montreal Neurological Institute and Hospital
Montreal
The Ottawa Hospital - General Campus
Ottawa
Sunnybrook Health Sciences Centre
Toronto
University of British Columbia
Vancouver
Croatia
Clinical Hospital Centre Zagreb
Zagreb
Denmark
Aalborg Universitetshospital
Aalborg
Aarhus Universitetshospital
Aarhus N
Rigshospitalet Glostrup
Glostrup Municipality
Odense Universitetshospital, Neurologisk Afdeling N
Odense C
Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
Sønderborg
Estonia
East Tallinn Central Hospital
Tallinn
West Tallinn Central Hospital
Tallinn
Tartu University Hospital
Tartu
Finland
Mehiläinen Neo Turku
Turku
France
CHU de Besancon Hopital Jean Minjoz
Besançon
Groupe Hospitalier Pellegrin
Bordeaux
Hopital neurologique Pierre Wertheimer - CHU Lyon
Bron
Hopital Gabriel Montpied CHU de Clermont-Ferrand
Clermont-ferrand
CH de Gonesse
Gonesse
CHU de Grenoble
La Tronche
Hopital Roger Salengro Service de Neurologie
Lille
CHU de la Timone - Hopital d Adultes
Marseille
Hopital Gui de Chauliac
Montpellier
Hopital Central - CHU de Nancy
Nancy
Hôpital Pasteur
Nice
CHU de Nîmes Hopital Caremeau
Nîmes
Groupe Hospitalier Pitié- Salpétrière
Paris
Hôpital de Poissy
Poissy
CHU de Rouen Hopital
Rouen
Höpital Hautepierre
Strasbourg
HIA de Toulon hôpital militaire
Toulon
Hungary
Budapesti Jahn Ferenc Dél-pesti Kórház és Rendel?intézet
Budapest
VALEOMED Diagnosztikai Központ
Esztergom
Ireland
St Vincents University Hospital
Dublin
Italy
AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi
Ancona
ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
Bergamo
Ospedale Bellaria
Bologna
Ospedale Binaghi
Cagliari
AOU Policlinico V. Emanuele - P.O G. Rodolico
Catania
Fondazione Istituto S. Raffaele - Giglio
Cefalù
Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
Chieti
AOU Careggi
Florence
AOUC Azienda Ospedaliero-Universitaria Careggi
Florence
Ospedale S.Antonio Abate
Gallarate
Irccs A.O.U.San Martino Ist
Genoa
Ospedale San Salvatore
L’aquila
Fond. Istituto Neurologico C.Besta
Milan
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan
IRCCS Ospedale San Raffaele
Milan
Ospedale Civile di Montichiari
Montichiari
A. O. U. Federico II
Napoli
Università degli Studi della Campania Luigi Vanvitelli
Napoli
Azienda Ospedaliera di Padova
Padua
AO Ospedali Riuniti Villa Sofia-Cervello
Palermo
AOU Policlinico Giaccone
Palermo
IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
Pavia
AO di Perugia - Ospedale S. Maria della Misericordia
Perugia
IRCCS Istituto Neurologico Neuromed
Pozzilli
Azienda Ospedaliera Sant'Andrea
Rome
Ospedale S.Camillo Forlanini
Rome
Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
Rome
Policlinico Universitario A. Gemelli
Rome
IRCCS Ospedale Casa Sollievo Della Sofferenza
San Giovanni Rotondo
AOU Senese - Presidio Ospedaliero Le Scotte
Siena
Policlinico G.B. Rossi
Verona
Kuwait
Ibn Sina Hospital
Kuwait City
Mexico
Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
Culiacán
Hospital General de México
Mexico City
Unidad de investigacion en salud (UIS)
Mexico City
Netherlands
Jeroen Bosch Ziekenhuis
's-hertogenbosch
Amsterdam UMC Location VUMC
Amsterdam
Amphia Ziekenhuis
Breda
Groene Hart Ziekenhuis
Gouda
Maasstadziekenhuis
Nl -rotterdam
Zuyderland Medisch Centrum - Sittard Geleen
Sittard-geleen
Elisabeth-TweeSteden Ziekenhuis
Tilburg
Norway
Haukeland universitetssykehus
Bergen
Sykehuset Buskerud HF
Drammen
Stavanger Universitetssykehus, Helse Stavanger HF
Stavanger
Poland
Neurocentrum Bydgoszcz sp. z o.o
Bydgoszcz
COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika
Gdansk
Care Clinic
Katowice
Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.
Krakow
Centrum Neurologii Krzysztof Selmaj
Lodz
Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.
Lublin
Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
Warsaw
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
Warsaw
Portugal
Hospital de Braga
Braga
HUC
Coimbra
Hospital Beatriz Angelo
Loures
Hospital Geral de Santo Antonio
Porto
Slovakia
Univerzitna nemocnica Bratislava
Bratislava
Univerzitna nemocnica Bratislava Nemocnica Ruzinov
Bratislava
Fakultna nemocnica Trnava
Trnava
Slovenia
University Medical Centre
Ljubljana
University Medical Centre Maribor
Maribor
Spain
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña
Hospital Vall d'Hebron
Barcelona
Hospital Puerta del Mar
Cadiz
Hospital General de Castellon
Castellon
Hospital Universitari de Girona Dr. Josep Trueta
Girona
Hospital Universitari de Bellvitge
L'hospitalet De Llobregat
Hospital Universitari Arnau de Vilanova de Lleida
Lleida
Hospital Universitario 12 de Octubre
Madrid
Hospital Universitario Clínico San Carlos
Madrid
Hospital Universitario La Paz
Madrid
Universitario de La Princesa
Madrid
Hospital Universitario Virgen de Arrixaca
Murcia
Hospital Universitario Central de Asturias
Oviedo
Hospital Quiron de Madrid
Pozuelo De Alarcón
Hospital Clinico Universitario de Valencia
Valencia
Hospital Universitario la Fe
Valencia
Complejo Hospitalario Universitario de Vigo - Xeral Cies
Vigo
Sweden
Sahlgrenska Sjukhuset
Gothenburg
Centralsjukhuset
Karlstad
Centrum för Neurologi
Stockholm
Turkey
Gazi University Medical Faculty
Ankara
Hacettepe University Medical Faculty
Ankara
Mustafa Kemal Ataturk UTF
Hatay
Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
Istanbul
Istanbul University Istanbul School of Medicine
Istanbul
Selcuk University Medical Faculty
Konya
Ondokuz Mayis University School of Medicine
Samsun
Karadeniz Tecnical Uni. Med. Fac.
Trabzon
United Kingdom
Royal Devon and Exeter Hospital (Wonford)
Exeter
Queen Elizabeth University Hospital
Glasgow
Raigmore Hospital
Inverness
Leeds Teaching Hospitals NHS Trust
Leeds
Charing Cross Hospital
London
Kings College Hospital
London
National Hospital for Neurology and Neurosurgery,
London
Royal Free Hospital
London
St George's Hospital
London
The Royal London Hospital
London
Royal Victoria Infirmary
Newcastle Upon Tyne
Salford Royal NHS Foundation Trust
Salford
Royal Hallamshire Hospita
Sheffield
Morriston Hospital
Swansea
Royal Cornwall Hospital
Truro
Time Frame
Start Date: 2018-07-12
Completion Date: 2025-07-17
Participants
Target number of participants: 1055
Treatments
Experimental: Ocrelizumab
Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
Related Therapeutic Areas
Sponsors
Leads: Hoffmann-La Roche